James M. Pellissier

2.3k total citations
58 papers, 1.8k citations indexed

About

James M. Pellissier is a scholar working on Economics and Econometrics, Oncology and Surgery. According to data from OpenAlex, James M. Pellissier has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Economics and Econometrics, 20 papers in Oncology and 12 papers in Surgery. Recurrent topics in James M. Pellissier's work include Health Systems, Economic Evaluations, Quality of Life (23 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Economic and Financial Impacts of Cancer (8 papers). James M. Pellissier is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (23 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Economic and Financial Impacts of Cancer (8 papers). James M. Pellissier collaborates with scholars based in United States, United Kingdom and Canada. James M. Pellissier's co-authors include Robbin Itzler, Ralph P. Insinga, Patricia Saddier, Alexander Nikas, Marc Brisson, Champ L. Baker, Ruifeng Xu, Myron J. Levin, Gordon B. Hazen and Frank Xiaoqing Liu and has published in prestigious journals such as PEDIATRICS, Cancer and Clinical Orthopaedics and Related Research.

In The Last Decade

James M. Pellissier

57 papers receiving 1.7k citations

Peers

Countries citing papers authored by James M. Pellissier

Since Specialization

Citations

This map shows the geographic impact of James M. Pellissier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Pellissier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Pellissier more than expected).

Fields of papers citing papers by James M. Pellissier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Pellissier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Pellissier. The network helps show where James M. Pellissier may publish in the future.

Co-authorship network of co-authors of James M. Pellissier

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Pellissier. A scholar is included among the top collaborators of James M. Pellissier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Pellissier. James M. Pellissier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models 2021 ·PharmacoEconomics ·Min Huang, Scott D. Ramsey, (unknown), Jipan Xie, James M. Pellissier, Andrew Briggs	6
2	A Holistic Approach to Evaluate the Cost-Effectiveness of Pembrolizumab with Multiple Indications: A Norway-Based Example 2018 ·Value in Health ·(unknown), James M. Pellissier, (unknown), (unknown)	2
3	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden 2018 ·European Urology Oncology ·(unknown), Vimalanand S. Prabhu, Haojie Li, Ruifeng Xu, (unknown), Yichen Zhong, James M. Pellissier, Rodolfo F. Perini, Ronald de Wit, Ronac Mamtani	15
4	MA14.10 Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Min Huang, Yanyan Lou, James M. Pellissier, Thomas Burke, (unknown), Vamsidhar Velcheti	1
5	Cost Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in the United States 2016 ·Value in Health ·(unknown), James M. Pellissier, Ruifeng Xu, (unknown), (unknown), Bartosz Chmielowski	7
6	Cost-Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal 2016 ·Value in Health ·L. Silva Miguel, (unknown), (unknown), (unknown), Ruifeng Xu, James M. Pellissier, P.A. Laires	2
7	Cancer Associated Medical Spending: US National Data Between 2000 and 2013 2016 ·Value in Health ·(unknown), (unknown), (unknown), James M. Pellissier	2
8	Cost-Effectiveness of Pembrolizumab in Patients with Advanced Melanoma Previously Treated with Ipilimumab in Portugal 2016 ·Value in Health ·L. Silva Miguel, (unknown), B. Pinheiro, (unknown), Ruifeng Xu, James M. Pellissier, P.A. Laires	2
9	Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients 2016 ·Value in Health ·Mo Huang, Yanyan Lou, James M. Pellissier, Thomas Burke, (unknown), Ruifeng Xu, (unknown)	3
10	Healthcare Resource Utilization in Patients Receiving Pembrolizumab or Docetaxel with Previously Treated Advanced NSCLC 2016 ·Value in Health ·Min Huang, James M. Pellissier, Jason J. Z. Liao	2
11	A Trial-Based Euroqol Eq-5d Health Utility Analysis in Patients with Previously Treated Advanced Nsclc 2016 ·Value in Health ·Min Huang, James M. Pellissier, Jason J. Z. Liao	6
12	Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore 2012 ·Value in Health Regional Issues ·Gilberto Lopes, Thomas Burke, James M. Pellissier, (unknown), Seema D. Dedhiya, Alexandre Chan	10
13	Comparative Costs of Ertapenem and Cefotetan as Prophylaxis for Elective Colorectal Surgery 2008 ·Surgical Infections ·Samuel E. Wilson, Robin S. Turpin, Ritesh Kumar, Kamal M.F. Itani, Erin Jensen, James M. Pellissier, Murray A. Abramson	12
14	Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany 2006 ·European Journal of Cancer ·Florian Lordick, B. Ehlken, Angela Ihbe‐Heffinger, Karin Berger, Karl J. Krobot, James M. Pellissier, Glenn Davies, Robert Deuson	41
15	The cost of chemotherapy-induced nausea and vomiting in Italy 2006 ·Supportive Care in Cancer ·Enzo Ballatori, Fausto Roila, Benedetta Ruggeri, (unknown), Mauro Iannopollo, (unknown), Giorgio Cruciani, Bruno Daniele, (unknown), James M. Pellissier, Robert Deuson	25
16	The incidence of herpes zoster in a United States administrative database 2005 ·Journal of General Internal Medicine ·Ralph P. Insinga, Robbin Itzler, James M. Pellissier, Patricia Saddier, Alexander Nikas	376
17	An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis 2003 ·Clinical Therapeutics ·Thomas J. Schnitzer, Sheldon X. Kong, (unknown), Panagiotis Mavros, Douglas J. Watson, James M. Pellissier, Walter L. Straus	7
18	Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis 2001 ·Clinical Therapeutics ·James M. Pellissier	31
19	Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis 2001 ·PharmacoEconomics ·John K. Marshall, James M. Pellissier, Cheryl Attard, Sheldon X. Kong, Michael Marentette	39
20	Introducing Patient Values into the Decision Making Process for Breast Cancer Screening 1997 ·Women & Health ·James M. Pellissier, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact